Saturday, December 21, 2024

PHARMA DEALS

REGULATORY UPDATES

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADZYNMA®▼ (recombinant ADAMTS13) for the treatment of ADAMTS13 deficiency in children and adult patients...

European Commission approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk

GSK plc (LSE/NYSE: GSK) today announced that the European Commission has authorised Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) for active immunisation for the prevention of...

CLINICAL UPDATES

ONCOLOGY

Stay Connected

16,985FansLike
2,458FollowersFollow
61,453SubscribersSubscribe

PHARMA MARKET ANALYSIS

Latest Reviews

Neuralink’s Blindsight: A Breakthrough in Vision Restoration

Neuralink, Elon Musk's brain-computer interface startup, has made significant strides in vision restoration technology. Their Blindsight device, recently granted FDA breakthrough device designation, aims...

BUSINESS STRATEGY

Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025

Theratechnologies, a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced a risk of a temporary supply disruption for EGRIFTA SV® (tesamorelin...

Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Merck for Mothers, the company’s global maternal health...

AbbVie Invested €150 M to Develop R&D Facility in Germany.

AbbVie breaks ground on a new central research building, “LUnA” (LUdwighafens neue Arbeitswelt) and is investing approximately €150 M in its second largest R&D...

Daiichi Sankyo Decided for RD Novare Closure

Daiichi Sankyo (TSE: 4568) said today that it has chosen for Daiichi Sankyo RD Novare closure (based in Edogawa-ku, Tokyo; hereinafter referred to as...

HEALTHCARE BLOG

Today on 18-July-2023, Flagship Pioneering, Inc. and Pfizer Inc. (NYSE: PFE) announced their collaboration to develop a fresh pipeline of cutting-edge pharmaceuticals. By utilising...

APPOINTMENTS

HEALTHCARE STARTUPS

WEEKLY NEWS

LATEST ARTICLES

Most Popular

Recent Comments